Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

COM701 · CGEN-15029

Monoclonal antibody · Immune activation, directed at PVRIG (CD112R) (PVRIG) · developed by Compugen

Phase 1/2 Most advanced trial
CGEN Developer
3 Registered trials

What is COM701?

COM701 is a humanized monoclonal antibody that binds PVRIG, an immune checkpoint receptor on cytotoxic T lymphocytes and natural killer cells. By blocking PVRIG's interaction with its ligand PVRL2, it is intended to relieve inhibition of T-cell and NK cell activation. It is being studied in multiple cancers, including ovarian, breast, lung, endometrial, colorectal and head and neck cancers, and multiple myeloma, alone or with nivolumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CGEN-15029
Drug type
Monoclonal antibody
Targets
PVRIG (CD112R) (PVRIG), PVRL2 (CD112, nectin cell adhesion molecule 2) (NECTIN2) (binding partner it blocks)
Mechanism
Immune activation, directed at PVRIG (CD112R) (PVRIG)
Pathways
T-cell and NK cell activation, immune checkpoint inhibition
Therapy area
Oncology
Developer
Compugen Ltd (CGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
IAY02XUV7L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06888921 Phase 1/2 Ovarian Cancer Active not recruiting CGEN
NCT04354246 Phase 1 Advanced Cancer Completed CGEN
NCT03667716 Phase 1 Advanced Cancer Completed CGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer RecurrentAdvanced CancerBreast CancerColo-rectal CancerColon CancerEndometrial CancerHNSCCLung CancerLung NeoplasmMicrosatellite Stable Colorectal CarcinomaMultiple MyelomaNeoplasm MalignantOvarian CancerOvarian Neoplasm

More from Compugen

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.

Follow CGEN, the company behind COM701

See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.